Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings

被引:0
作者
Cheng, David [1 ,2 ]
Rieu-Werden, Meghan L. [2 ]
Lykken, Jacquelyn M. [3 ]
Werner, Claudia L. [4 ,5 ]
Feldman, Sarah [6 ]
Silver, Michelle I. [7 ]
Atlas, Steven J. [2 ]
Tiro, Jasmin A. [8 ]
Haas, Jennifer S. [2 ]
Kamineni, Aruna [9 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA USA
[3] Univ Texas Southwestern Med Ctr, Peter Odonnell Jr Sch Publ Hlth, Dallas, TX USA
[4] Univ Southwestern Med Ctr, Dept Obstet & Gynecol, Dallas, TX USA
[5] Parkland Hlth, Dallas, TX USA
[6] Harvard Med Sch, Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA USA
[7] Washington Univ, Dept Surg, Sch Med, Div Publ Hlth Sci, St. Louis, MO USA
[8] Univ Chicago, Dept Publ Hlth Sci, Biol Sci Div, Chicago, IL USA
[9] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
关键词
2006 CONSENSUS GUIDELINES; AMERICAN SOCIETY; FOLLOW-UP; WOMEN; COLPOSCOPY; BREAST; TESTS;
D O I
10.1158/1055-9965.EPI-23-1564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Follow-up of abnormal results is essential to cervical cancer screening, but data on adherence to follow-up are limited. We describe patterns of follow-up after screening abnormalities and identify predictors of guideline-concordant follow-up.Methods: We identified the index screening abnormality (positive human papillomavirus test or atypical squamous cells of undetermined significance or more severe cytology) among women of ages 25 to 65 years at three US healthcare systems during 2010 to 2019. We estimated the cumulative incidence of surveillance testing, colposcopy, or treatment after the index abnormality and initial colposcopy. Logistic regressions were fit to identify predictors of guideline-concordant follow-up according to contemporaneous guidelines.Results: Among 43,007 patients with an index abnormality, the cumulative incidence of any follow-up was 49.6% by 4 years for those with atypical squamous cells of undetermined significance/human papillomavirus-negative and higher for abnormalities warranting immediate colposcopy. The 1-year cumulative incidence of any follow-up after colposcopy was 70% for patients with normal results or cervical intraepithelial neoplasia I and 90% for patients with cervical intraepithelial neoplasia II+. Rates of concordant follow-up after screening and colposcopy were 52% and 47%, respectively. Discordant follow-up was associated with factors including age, race/ethnicity, overweight/obese body mass index, and specific types of public payor coverage or being uninsured.Conclusions: Adherence to the recommended follow-up of cytologic and histopathologic abnormalities is inconsistent in clinical practice. Concordance was poor for mild abnormalities and improved, although suboptimal, for more severe abnormalities.Impact: There remain gaps in the cervical cancer screening process in clinical practice. Further study is needed to understand the barriers to the appropriate management of cervical abnormalities.
引用
收藏
页码:912 / 922
页数:11
相关论文
共 40 条
  • [31] Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort
    Elit, L.
    Saskin, R.
    Raut, R.
    Elliott, L.
    Murphy, J.
    Marrett, L.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (01) : 95 - 100
  • [32] Optimizing biopsy procedures during colposcopy for women with abnormal cervical cancer screening results: a multicenter prospective study
    Nakamura, Yuko
    Matsumoto, Koji
    Satoh, Toyomi
    Nishide, Ken
    Nozue, Akiko
    Shimabukuro, Koji
    Endo, Seiichi
    Nagai, Kimihiro
    Oki, Akinori
    Minaguchi, Takeo
    Morishita, Yukio
    Noguchi, Masayuki
    Yoshikawa, Hiroyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 579 - 585
  • [33] Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors
    Munshi, Vidit N.
    Perkins, Rebecca B.
    Sy, Stephen
    Kim, Jane J.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (02) : 228.e1 - 228.e9
  • [34] An on-going study of three different cervical cancer screening strategies based on primary healthcare facilities in Beijing China
    Han, Lili
    Chang, Xinlei
    Song, Peige
    Gao, Lili
    Zhang, Yue
    An, Lin
    Shen, Jie
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2020, 13 (04) : 577 - 583
  • [35] Recommendations for the prevention, screening, diagnosis, staging, and management of cervical cancer in areas with limited resources: Report from the International Gynecological Cancer Society consensus meeting
    Maluf, Fernando Cotait
    Dal Molin, Graziela Zibetti
    de Melo, Andreia Cristina
    Paulino, Eduardo
    Racy, Douglas
    Ferrigno, Robson
    Serrano Uson Junior, Pedro Luiz
    Ribeiro, Reitan
    Moretti, Renato
    Sadalla, Jose Carlos
    Nogueira-Rodrigues, Angelica
    Carvalho, Filomena Marino
    Baiocchi, Glauco
    Callegaro-Filho, Donato
    Abu-Rustum, Nadeem R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Impact of healthcare access and HIV testing on utilisation of cervical cancer screening among US women at high risk of HIV infection: cross-sectional analysis of 2016 BRFSS data
    Zhang, Dongyu
    Advani, Shailesh
    Huchko, Megan
    Braithwaite, Dejana
    BMJ OPEN, 2020, 10 (01):
  • [37] Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a US healthcare system: The STEP trial
    Winer, Rachel L.
    Lin, John
    Anderson, Melissa L.
    Tiro, Jasmin A.
    Meenan, Richard T.
    Hansen, Kristina
    Gao, Hongyuan
    Sparks, Angela
    Greene, Dina N.
    Kilgore-Martin, Sony
    Green, Beverly B.
    Buist, Diana S. M.
    CONTEMPORARY CLINICAL TRIALS, 2022, 122
  • [38] Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a US healthcare system
    Winer, Rachel L.
    Tiro, Jasmin A.
    Miglioretti, Diana L.
    Thayer, Chris
    Beatty, Tara
    Lin, John
    Gao, Hongyuan
    Kimbel, Kilian
    Buist, Diana S. M.
    CONTEMPORARY CLINICAL TRIALS, 2018, 64 : 77 - 87
  • [39] Diagnosis, Therapy and Follow-up of Cervical Cancer Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy
    Beckmann, Matthias W.
    Stuebs, Frederik A.
    Koch, Martin C.
    Mallmann, Peter
    Dannecker, Christian
    Dietl, Anna
    Sevnina, Anna
    Mergel, Franziska
    Lotz, Laura
    Hack, Carolin C.
    Ehret, Anne
    Gantert, Daniel
    Martignoni, Franca
    Cieslik, Jan-Philipp
    Menke, Jan
    Ortmann, Olaf
    Stromberger, Carmen
    Oechsle, Karin
    Hornemann, Beate
    Mumm, Friederike
    Grimm, Christoph
    Sturdza, Alina
    Wight, Edward
    Loessl, Kristina
    Golatta, Michael
    Hagen, Volker
    Dauelsberg, Timm
    Diel, Ingo
    Munstedt, Karsten
    Merz, Eberhard
    Vordermark, Dirk
    Lindel, Katja
    Wittekind, Christian
    Kuppers, Volkmar
    Lelle, Ralph
    Neis, Klaus
    Griesser, Henrik
    Poschel, Birgit
    Steiner, Manfred
    Freitag, Ulrich
    Gilster, Tobias
    Schmittel, Alexander
    Friedrich, Michael
    Haase, Heidemarie
    Gebhardt, Marion
    Kiesel, Ludwig
    Reinhardt, Michael
    Kreissl, Michael
    Kloke, Marianne
    Horn, Lars-Christian
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02) : 139 - 179
  • [40] Diagnosis, Therapy and Follow-up of Cervical Cancer Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities
    Fehm, Tanja
    Stuebs, Frederik A.
    Koch, Martin C.
    Mallmann, Peter
    Dannecker, Christian
    Dietl, Anna
    Sevnina, Anna
    Mergel, Franziska
    Lotz, Laura
    Ehret, Anne
    Gantert, Daniel
    Martignoni, Franca
    Cieslik, Jan-Philipp
    Menke, Jan
    Ortmann, Olaf
    Stromberger, Carmen
    Oechsle, Karin
    Hornemann, Beate
    Mumm, Friederike
    Grimm, Christoph
    Sturdza, Alina
    Wight, Edward
    Loessl, Kristina
    Golatta, Michael
    Hagen, Volker
    Dauelsberg, Timm
    Diel, Ingo
    Muenstedt, Karsten
    Merz, Eberhard
    Vordermark, Dirk
    Lindel, Katja
    Wittekind, Christian
    Kueppers, Volkmar
    Lelle, Ralph
    Neis, Klaus
    Griesser, Henrik
    Poeschel, Birgit
    Steiner, Manfred
    Freitag, Ulrich
    Gilster, Tobias
    Schmittel, Alexander
    Friedrich, Michael
    Haase, Heidemarie
    Gebhardt, Marion
    Kiesel, Ludwig
    Reinhardt, Michael
    Kreissl, Michael
    Kloke, Marianne
    Horn, Lars-Christian
    Wiedemann, Regina
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02) : 181 - 204